SIGA Technologies (SIGA) Corporate presentation summary

Leadership in infectious disease and health security

• Focuses on innovative medicines for orthopoxviruses, with TPOXX as a foundational product.

• Operates a fully integrated, U.S.-based supply chain for oral TPOXX.

• Senior management team has deep expertise in infectious diseases and government relations.

• Strategic priorities include expanding regulatory approvals, global partnerships, and moving into complementary therapeutic areas.

The smallpox threat and preparedness

• Smallpox remains a significant global threat due to high mortality and lack of widespread vaccination.

• Geopolitical instability and synthetic biology advancements increase outbreak risks.

• Vaccines alone may not suffice; antivirals like TPOXX are critical for comprehensive preparedness.

• Historical milestones highlight ongoing vigilance and the need for robust countermeasures.

TPOXX product differentiation and approvals

• TPOXX is the first FDA-approved antiviral for smallpox, with approvals in the U.S., Canada, EU, UK, and Japan.

• Demonstrates strong efficacy in animal models and safety in over 1,300 human volunteers.

• Targets the VP37 protein, preventing viral spread within the body.

• Well-tolerated compared to other antivirals and vaccines, with no serious adverse events reported.

• Expansion into post-exposure prophylaxis (PEP) could address current health security gaps.